Phoebe trial
WebbASCO 2024 (Oral) - [VIRTUAL] Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial. Log in to view document ASCO … Webb25 feb. 2024 · Pyrotinib plus capecitabine versus lapatinib plus capecita bine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol; Advance online publication 11 February 2024.DOI: 10.1016/S1470-2045(20)30702-6
Phoebe trial
Did you know?
Webb24 jan. 2024 · Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2024 Virtual Meeting. EP: 1. Coming Soon, HER2 …
Webb28 mars 2024 · The phase III PHOEBE trial was designed to compare pyrotinib plus capecitabine with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with... Webb10 dec. 2024 · In an updated analysis of the PHOEBE trial, 66.6% of patients treated with pyrotinib plus capecitabine were alive after 2 years compared with 58.8% of those on …
Webb23 feb. 2024 · PHOEBE (NCT03080805): a phase 3 trial examining pyrotinib plus capecitabine vs lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer 2; and Webb28 mars 2024 · The phase III PHOEBE trial enrolled 267 patients from China with pathologically confirmed HER2-positive metastatic breast cancer. All patients had been previously treated with trastuzumab and taxanes, with a maximum of 2 lines of prior chemotherapy in the metastatic setting.
Webb23 dec. 2024 · Updated results from the PHOEBE trial The phase 3 PHOEBE trial evaluated the efficacy of pyrotinib (an irreversible tyrosine kinase inhibitor targeting EGFR, HER2 and HER4) plus capecitabine compared with lapatinib plus capecitabine, in 267 Chinese patients with HER-2 positive mBC, previously treated with trastuzumab and taxanes.
Webb17 dec. 2024 · The PHOEBE trial enrolled 267 Chinese women with HER2-positive metastatic breast cancer who had been previously treated with trastuzumab and taxanes and up to two prior lines of chemotherapy in the metastatic setting. Half were randomly allocated to pyrotinib plus capecitabine and half to lapatinib plus capecitabine. polymyxin b units to mg conversionWebb9 dec. 2024 · Xu, B. Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2 … polymyxin b units to mgWebb28 maj 2024 · 1001 Background: The Phase III MONALEESA-3 trial (NCT02422615) previously demonstrated a statistically significant improvement in OS with RIB, a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), plus FUL compared with placebo (PBO) plus FUL as first-line (1L) or second-line (2L) treatment in postmenopausal pts with HR+/HER2− … polymyxin b ungWebb25 maj 2024 · Benefits in objective response rate, clinical benefit rate, and duration of response with pyrotinib plus capecitabine were also indicated (Table). The most … shanley keane kilmovee facebookWebbIn the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER inhibitor) plus capecitabine after previous trastuzumab. Methods: … shanley hotel napanoch new yorkWebb28 maj 2024 · Background: The Phase III MONALEESA-3 trial (NCT02422615) previously demonstrated a statistically significant improvement in OS with RIB, a cyclin-dependent … polymyxine antibioticaWebb14 dec. 2024 · medwireNews : The PHOEBE trial has demonstrated a significant overall survival (OS) benefit with the use of the multikinase inhibitor pyrotinib compared with … shanley hotel in napanoch